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Abstract
Retinoic acid receptor (RAR) signaling is important for regulating transcriptional activity of genes involved in growth,
differentiation, metabolism and reproduction. Defects in RAR signaling have been implicated in cancer. TEL, a member of
the ETS family of transcription factors, is a DNA-binding transcriptional repressor. Here, we identify TEL as a transcriptional
repressor of RAR signaling by its direct binding to both RAR and its dimerisation partner, the retinoid x receptor (RXR) in a
ligand-independent fashion. TEL is found in two isoforms, created by the use of an alternative startcodon at amino acid
43. Although both isoforms bind to RAR and RXR in vitro and in vivo, the shorter form of TEL represses RAR signaling
much more efficiently. Binding studies revealed that TEL binds closely to the DNA binding domain of RAR and that both
Helix Loop Helix (HLH) and DNA binding domains of TEL are mandatory for interaction. We have shown that repression by
TEL does not involve recruitment of histone deacetylases and suggest that polycomb group proteins participate in the
process.
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Introduction
Nuclear receptors (NR) belong to the large family of well
studied transcription factors that are important for growth,
differentiation, metabolism and reproduction in higher organ-
isms. Small molecules, such as steroids, thyroid hormones and
retinoids serve as ligands and bind to the ligand binding
domains (LBDs). NRs bind DNA of target promotors as hetero
or homo dimers using their highly homologous DNA binding
domain (DBD) [1]. One of these NR, the retinoic acid receptor
(RAR) has several isoforms, forms a heterodimer with retinoic-
x-receptor (RXR), and binds the ligand all-trans retinoic acid
(ATRA). RAR-signaling induces differentiation and apoptosis
in a wide variety of cells. Furthermore, retinoic acid has tumor-
suppressive activity and defects in RAR signaling are implicat-
ed in cancers [2,3].
The regulation of gene expression by NR involves the release
and binding of co-repressor and co-activator complexes. Nuclear
receptor co-repressor (N-CoR) and silencing mediator of retinoid
and thyroid hormone receptors (SMRT) are co-repressors that
associate with RAR and recruit complexes with histone deacety-
lase (HDAC) activity [4,5]. Activation of RAR target genes
involves the binding of co-activators of the p160 family (SRC1,
SRC2 also known as Tif2, and SRC3 also known as RAC3) of
which most of these have intrinsic histone acetylase (HAT) activity.
In addition, HAT activity-containing p300/CBP proteins are
recruited by these co-activator complexes [6,7]. Recent studies
have shown that both active and repressed RAR-regulated genes
continuously exchange co-activator and co-repressor complexes
[8,9]. This dynamic and cyclic process cause a continuous
recruitment of both HAT and HDAC activity to the promoters
and the balance between these complexes finally results in either
activation or repression of gene expression. In addition, various
other processes including ubiquitination, sumoylation, methylation
and phosphorylation have been implicated in regulation of NR
activity [9,10,11,12].
Here we describe a novel mode of repression of RAR signaling.
The repression involves the binding of the transcriptional
repressor TEL to RARa and RXRa. TEL (ETV6) is a member
of the ETS family of transcription factors. TEL is expressed
throughout the body including the hematopoietic system and is
crucial for hematopoietic stem cell maintenance, as has been
shown in a Tel knockout mice model [13]. These mice have been
shown to die due deficient yolk sac angiogenesis. The classical
mode of repression by TEL has been studied extensively and
involves the binding of TEL to DNA-responsive elements within
promoters with its DBD domain. The helix-loop-helix (HLH)
domain, also called Pointed (PNT) or SAM domain is important
for polymerization of TEL [14,15]. Repression involves either the
recruitment of co-repressor complexes and HDACs [16,17], or
the recruitment of L(3)MBT-containing polycomb group-com-
plexes [18] that facilitate long-term repression by chromatin
remodeling other than deacetylase activity. Here we show that
the interaction between TEL, RARa and RXR involves both
DBD and HLH domains of TEL and the DBD domain of RARa.
Furthermore, we show that both isoforms of TEL, generated by
the use of an alternative start codon, influence RAR signaling,
that this repression is HDAC-independent, and that the shorter
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isoform is a much more efficient repressor compared to the larger
isoform.
Methods
Constructs
All expression constructs are derived from the CMV promoter
containing expression vector pcDNA3. TEL, MN1 and MN1-
TEL constructs have been described previously [19,20]. The DBD
mutant of TEL was described elsewhere [21] and was recloned in
a pcDNA3 vector. The point mutation in the HLH domain in
TEL was introduced using site-directed mutagenesis (Quikchange
mutagenesis kit, Stratagene). The primerset used was 59-cctcatt-
caggtgatgcggcctatgaac tccttcagc-39 in combination with a primer
that consists of the opposite strand. The DBD mutation was
combined with the HLH mutant by ligating the BstEII/ScaI
fragment from a pcDNA3 TEL-DBD mutant construct into the
corresponding sites of the digested HLH mutant constructs. The
HA-tagged version of TEL was created by ligating a double
stranded oligo containing the DNA sequence for a spacer
encoding amino acids GAGAGA followed by the HA sequence
and a stop codon, in frame with the last amino acid of TEL. TEL
constructs with a forced start at methionine 1 or 43 were created
using the Quikchange mutagenesis kit by changing the methionine
into a cysteine. Deletion constructs of TEL were generated by
PCR using primers containing restriction sites enabling cloning
and fusion of the specified regions. The RARE-luc reporter vector
contains 3 retinoic acid responsive (DR5) elements in a basic TK
luc reporter vector and was a kind gift of Dr. J.Jansen (Dept. of
Hematology, Erasmus MC, Rotterdam, the Netherlands). The
MSV-luc reporter construct was previously described [20] and
the RARE3-MSV reporter was created contains three RARE
elements cloned in front of 131 bp of the original MSV promoter.
The putative ETS element within the remaining sequence,
TTCC, was mutated into TTTT using the Quik Change
Mutagenesis Kit. Plasmid pSG5-TIF2 was obtained from Dr. G.
Jenster (Urology, Erasmus MC, Rotterdam, the Netherlands) and
GST-RAR, GST-RAR-LBD, GST-RXR and GST-RXR-LBD
constructs were a kind gift of Dr. H. Gronemeyer (IGBMC,
Strasbourg, France). Additional deletion constructs of GST-RAR
were generated by subcloning using restriction sites available in the
RARa sequence. A bioV5-tagged version of deletion construct N3
of RAR was created by linking the bioV5 sequence [22] at the N-
terminus of RAR-N3. pSG513-BirA plasmid for expression of the
BioLigase was a kind gift of T.B. van Dijk (Dept of Cell Biology,
Erasmus MC, Rotterdam, the Netherlands) [23]. All constructs
were checked by DNA sequencing (BigDye Terminator kit,
Stratagene) and, in case of expression vectors, also by in vitro
transcription/translation to confirm that translation products of
the correct length were obtained (TNT Quick Coupled Tran-
scription/Translation system, Promega, Madison, WI, USA).
Transfection
The Hep3B cell line (human hepatocarcinoma) [24] was
cultured in a-MEM, supplemented with 5% (v/v) fetal bovine
serum and antibiotics (penicillin and streptomycin). Hep3B cells
were seeded at a density of 0.6?105 cells per well in 24-well culture
plates. 24 hours after seeding the cells the medium was replaced
with fresh medium, containing all-trans retinoic acid (ATRA,
Sigma Aldrich, St. Louis, MO, USA), when indicated, at a
concentration of 1 mM. After 1–2 hours the cells were transfected
with the indicated amounts of DNA, using FuGENE 6
Transfection Reagent (Roche Applied Science, Basel, Switser-
land), according to the manufacturer’s instructions. In each
experiment, the total amount of transfected DNA as well as the
molar amount of expression plasmid was kept constant, by
addition of the required amount of pUC6 and empty pcDNA3
plasmid. When applicable, three hours after transfection Trichos-
tatin A (TSA; Sigma Aldrich) was added to the specified
concentration from ethanol stocks. 24 or 48 hours after transfec-
tion luciferase activities were measured in lysates on a Fluoroscan
Ascent FL luminometer (Labsystems, Helsinki, Finland).
GST pull down
GST fusion constructs were expressed in E. coli and the fusion
proteins were loaded onto glutathion sepharose beads (GE
Healthcare, Uppsala, Sweden) according to the manufacturer’s
recommendations. The amount of GST protein (mg) used for
loading was similar for the different fusion proteins in each
experiment. When necessary, because of varying levels of GST
fusion protein expression, untransformed E. coli lysate was added
during loading of the beads, to keep also the total amount of lysate
(mg protein) at similar levels. Binding of proteins to the
immobilized GST fusion proteins was carried out as described
by Van Wely et al [25] with the exception that instead of using
columns, the beads were incubated and washed in microfuge tubes
and collected by centrifugation at maximal speed. Beads
containing non-fused GST were used as controls. In vitro
transcription/translation products labeled with 35S-methionine
were used for the binding experiments. The bound translation
products were eluted from the beads by boiling in SDS-PAGE
sample buffer, separated by SDS-PAGE, and visualized by
autoradiography.
Immunoprecipitation
2?106 Hep3B cells were transfected with pcDNA3, pcDNA3
TEL-HA M1C or pcDNA3 TEL-HA M43C in combination with
pcDNA3 BioV5-RARN3 and BirA plasmids using Fugene
6 transfection reagent (Roche) according to manufacturer’s
protocols. 48 hours after transfection, cells were harvested and
subsequently lysed using a buffer containing 20 mM Tris pH 8.0,
137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA (pH 8.0)
supplemented with Complete Mini protease inhibitor cocktail 9
(Roche). BioV5 RAR-N3 proteins were precipitated using
streptavidin-coated Dynabeads (Invitrogen Dynal AS, Oslo,
Norway). Precipitated proteins were subjected to SDS PAGE
and Western blotting according to standard protocols. Antibodies:
a-TEL, clone 3B10 (Abnova, Taipei, Taiwan); a-HA, biotin-
tagged, clone 3F10 (Roche); streptadivin-HRP, (BioGenex Labo-
ratories Inc., San Ramon, CA, USA)
Results
TEL binds directly to RARa and RXRa
The transcriptional cofactor MN1 stimulates and inhibits RAR/
RXR-mediated transcription [26]. In order to investigate if MN1
bound to RARa and/or RXRa we performed GST pulldown
experiment using GST-fused RARa (GST-RARa) and GST-
RXRa together with in vitro produced and 35S-labeled proteins.
MN1 was unable to bind to GST-RARa and RXRa (Figure 1A).
Other cofactors are thus involved in this transcription regulation.
In this experiment we also tested the MN1-TEL protein. This
leukemogenic protein is formed by an AML-causing translocation
(12;22) between MN1 and TEL genes. To our surprise, MN1-TEL
bound very strongly to RARa and RXRa. In order to locate the
domain that binds RARa and RXR we investigated whether
binding was a property of the TEL moiety in the MN1-TEL
protein. This indeed appeared to be the case as is shown in
TEL Inhibits RAR-RXR-Mediated Transcription
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figure 1A, right panel. The presence of an alternative start
methionine at aa 43 of the coding region of the TEL gene gives rise
to two isoforms of TEL [27,28]. Both isoforms of TEL bound
GST-RARa and GST-RXRa equally efficiently in this GST
pulldown assay.
TEL binds to the DBD domain of RAR whereas the
coactivator Tif2 binds to the ligand binding domain
Tif2, also known as SRC2, is a coactivator of RAR that binds
the ligand binding domain (LBD) in a ligand dependent fashion
[7]. The LxxLL motif of Tif2 provides the binding interface. TEL
also harbors a LxxLL motif (aa 113–117, LYELL) within the HLH
domain and this prompted us to investigate the possibility that Tif2
and TEL are displaying similar binding characteristics. We
obtained and generated deletion constructs of RARa and RXRa
that harbor the different regions of the receptor (Figure 1B).
Pulldowns using these constructs showed that Tif2 could bind to
RARa but not to RXRa. TEL interacted with both RARa and
RXRa constructs. The RARa and RXRa deletion constructs
showed that TEL interacted with RARa constructs that contain
the AF1 and DBD regions of RARa, whereas Tif2 interacted with
the LBD region (Figure 1B). The binding of TEL was independent
of the ligand ATRA, whereas the binding of Tif2 was lost if ATRA
was not available (data not shown). The smallest RARa construct
tested only contains the CTE region of the DBD. This construct
was efficiently expressed but TEL failed to bind this region (data
not shown). From these experiments we conclude that the binding
of TEL to RARa and RXRa is within or close to the DBD
Figure 1. TEL binds RAR and RXR in vitro and in vivo. (A) TEL and MN1-TEL bind RAR and RXR whereas MN1 does not. In vitro generated, 35S-
labeled proteins, as shown in the input lanes, were used for GST pulldowns with GST-RAR, GST-RXR and GST (as control). (B) TEL binds the DBD
domain of RARa. Upper panel: Schematic overview of the RARa and RXRa constructs. The domains within RARa and RXRa are indicated with letters
commenly used to indicate the domains within the nuclear receptor family. At the bottom the different regions are indicated with respect to their
function. AF1, Activator function 1; DBD, DNA binding domain; CTE, C-terminal extension; LBD, ligand-binding domain; AF2, activator function 2.
Lower panel: GST pulldowns with in vitro transcribed/translated TEL and TIF2. Binding of TEL to RAR and RXR differs from the binding of TIF2 to RARa
and RXRa. Binding of TIF2 was detected for LB-containing RARa constructs whereas TEL bound to the DBD region of RARa. No binding of TEL to the
AF1 and first part of DBD was detected (GST-RAR-N2). (C) HLH and DBD domains of TEL are crucial for binding to RARa. Upper panel: Schematic
overview of deletion constructs of TEL. Numbers indicate the amino acid positions. Middle left: ITT products were used for GST pulldown assays with
GST-RAR-N3. Middle right: Only deletion constructs that contain both HLH and DBD domains were detected in the in vitro binding assay. Lower
panel: WT TEL showed binding to GST-RARa, whereas HLH, DBD or double mutant TEL proteins failed to bind GST-RARa. (D) bio-precipitation of
bioV5-tagged RAR-N3 proteins. Only in the presence of bioV5-tagged RARN3, TEL-HA proteins were detectable in the precipitations, showing the in
vivo binding between TEL and RAR. Right panel shows input lysates. TEL proteins were detectable with both a-TEL and a-HA antibodies.
doi:10.1371/journal.pone.0023620.g001
TEL Inhibits RAR-RXR-Mediated Transcription
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domain of RARa and that it differs from the binding of Tif2 to
RARa, which is ligand-dependent.
Both the HLH domain and the DBD of TEL are required
for binding
The TEL protein is member of the ETS family of transcription
factors that have several domains in common. We have generated
deletion constructs to investigate which domains of the protein are
crucial for binding to RARa. A schematic overview is shown in
Figure 1C. All constructs were efficiently produced in the in vitro
transcription/translation system (middle left panel of Figure 1C)
and were used in pulldown experiments (middle right panel of
Figure 1C). All constructs that contain both the HLH and DBD
domains of TEL were binding to RARa whereas other constructs
failed to bind. Both HLH and DBD domains of TEL are thus
crucial for binding to RARa. It has also been described that the
HLH domain of TEL causes aggregation of TEL in vitro and this
could result in entrapping of other proteins. Such a a-specific
entrapping of proteins does not explain the interactions shown in
Figure 1 since (1) we do not see interaction with GST, and (2) we
also do not see any interaction with two TEL mutants in which the
polymerization domain is still intact, i.e. the TEL-DBDmutant
and the deletion mutant HCE.To investigate whether also small
point mutations within the DBD and HLH domains of TEL can
abrogate the interaction between TEL and RARa we generated
two mutants of TEL. The mutations within the HLH domain of
TEL (V112A/L113A) are located in the binding surface of the
HLH structure important for polymerization. This mutant is
impaired in polymerization (data not shown). The DBD mutant of
TEL (R396L, R399L) was described previously [21,29] and fails to
bind ETS responsive elements. In our in vitro binding assay with
GST-RARa both TEL mutants were tested for interaction with
RARa. Figure 1C, lower panel shows that these TEL mutants
failed to bind RARa. From this we conclude that both HLH and
DBD domains are crucial for binding to RARa and that mutations
that impair the function of these domains also disrupt binding of
TEL to RARa.
In vivo binding of TEL and RAR
To examine the interaction between TEL and RAR in vivo, we
transfected Hep3B cells with an expression plasmid of N-terminal
part of RARa (RAR-N3) tagged with a V5 and bio tag at the N-
terminus and a M43-TEL-HA or M1-TEL-HA construct. RAR
proteins were precipitated on the bio tag using streptavidin beads
and precipitates were subjected to immunoblotting for TEL
proteins. TEL-HA proteins, detected with either an antibody
against TEL or the HA-tag, co-precipitated with RAR-N3 protein.
No signal for TEL proteins was observed in negative control
precipitations (Figure 1D).
M43-TEL represses transcription directed by the nuclear
receptor dimer RAR/RXR
The binding of TEL to RARa and RXRa prompted us to
investigate if TEL can also repress transcription that is regulated
by the nuclear receptor heterodimer RAR/RXR. In Hep3B cells,
the retinoic acid-responsive element (RARE) from the RARb
promoter cloned in front of a TK promoter (Figure 2A) was
strongly stimulated by ATRA (data not shown), which activates
endogenously expressed RAR and RXR. Although both isoforms
of TEL are binding to RARa and RXRa, only the shorter isoform
(M43-TEL) exhibited repression activity on this promoter
(Figure 2B) in this assay. The moloney sarcoma virus long
terminal repeat (MSV-LTR) is a viral promoter that is regulated
by numerous transcription factors [30,31]. We have shown
previously that the MSV promoter harbors a genuine RAR/
RXR-responsive element (RARE), also known as a direct repeat 5
(DR5) element [25]. The remainder of the sequence has at least
five potential ETS-responsive elements that possibly represent
target sequences for TEL. Both isoforms of TEL strongly repressed
the activity of the MSV-LTR although the shorter isoform (M43-
TEL) was more efficient (Figure 2C). The extent of the repression
was much greater compared to the repression observed on the
RARE luc reporter. We hypothesized that on this viral promoter,
the repressive effects on ETS elements are combined with
repression by TEL via the RAR/RXR dimer. In order to
investigate repression on the RARE element in the context of the
MSV-LTR, we juxtaposed three copies of the RARE element
from the MSV promoter adjacent to the 39 region of the MSV-
LTR, which harbors crucial elements like the TATA box and
CAAT box, thereby deleting all but one ETS element. This
remaining putative ETS element, which is located between the
TATA and CAAT boxes, was removed by mutating two C’s into 2
T’s (Figure 2A). The resulting promoter, called RARE3-MSV, was
repressed by TEL and the extent of the repression was lower
compared to the original MSV-LTR constructs (Figure 2D) but
somewhat higher when compared to the RARE luc constructs.
The larger isoform of TEL (M1-TEL) still had some residual
repression on this construct.
Besides HLH and DBD domains, other regions of TEL are
important for repression of RAR/RXR-mediated
transcription
We next tested the ability of the TEL deletion mutants and point
mutants to repress the activity of the MSV LTR and the RARE
reporter plasmids in Hep3B cells (Figure 3A). The classical mode of
repression by TEL is conducted on the MSV reporter and involves
the binding to ETS elements. Although the HD deletion mutant
lacks the central region of the TEL protein, that is crucial for
the recruitment of corepressors N-CoR and SMRT [16,17,32], it
still was able to repress transcription of the MSV-LTR. Either
recruitment of mSIN3A via the HLH domain is sufficient for
repression or dimerization with other intact TEL molecules that are
endogenously expressed in Hep3B cells provides the interface for
recruitment of other co-repressors. In contrast, the repression of
RAR-RXR-responsive elements fully depends on regions other than
the HLH and DBD domains of TEL. Whereas M43-TEL inhibited
the activity of the RARE luc or RARE3-MSV reporter, none of the
tested deletion mutants did. The results of the DBD mutants were
inconsistent. DBD deletion mutants were unable to repress the
reporters whereas TEL that contains point mutations within the
DBD (TEL-DBDm) was capable of low-level repression (data not
shown). TEL proteins that either contain a point mutation in or a
deletion of the DBD domain localized exclusively to the cytoplasm
and therefore their effect on RAR/RXR-induced expression could
not be tested. Next we investigated if the HLH mutant construct,
which is unable to polymerize with itself, but showed some residual
polymerization with wildtype TEL (data not shown), was able to
carry out either mode of repression. Figure 3B shows that this
mutant was unable to repress any of the two reporters. From this we
conclude that dimerization of TEL proteins is important for
repression on ETS elements that are present in the MSV_LTR.
Repression of RAR/RXR-mediated transcription is HDAC
independent
The recruitment of co-repressor complexes that subsequently
interact with histone deacetylases (HDACs) is one of the ways in
TEL Inhibits RAR-RXR-Mediated Transcription
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e23620
Figure 2. TEL represses transcription that is mediated by the heterodimer RAR/RXR. (A) Schematic overview of different luciferase reporter
constructs RARE-luc, MSV-luc and RARE3MSV-luc. (B) The M43-TEL isoform inhibits the RARE luc reporter whereas the M1-TEL isoform does not. (C)
The viral promoter MSV is repressed by both isoforms of TEL. M43-TEL is more efficient. (D) Both TEL isoforms repress the RARE3 MSV-luc construct.
M43-TEL is more efficient. All transfections were performed in the presence of all-trans retinoic acid (ATRA).
doi:10.1371/journal.pone.0023620.g002
Figure 3. Deletion mutants of TEL have no repressive activity. (A) Three different reporters were tested with TEL deletion mutants. The
repression of TEL on the RAR-RXR dimer (i.e. RARE luc and RARE3-MSV luc) was only detected using full length M43 TEL. Although deletion mutant
HD was able to bind RAR in vitro (figure 1), it was unsuccessful in repression. The MSV-luc reporter contains not only an RAR/RXR responsive element
but also many possible ETS binding sites (figure 2E). The HD deletion construct of TEL repressed the MSV-luc reporter efficiently. (B) Both modes of
repression by TEL (i.e. on RAR/RXR and on ETS sites) are disabled in the HLH mutant of TEL (TEL-V112A/L113A).
doi:10.1371/journal.pone.0023620.g003
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which TEL represses transcription when it binds to TEL
responsive elements. Whether such mechanisms are also involved
in the repression of RAR/RXR-mediated transcription by TEL
was tested using trichostatin (TSA). TSA is a strong inhibitor of
deacetylases and is expected to abrogate repression by TEL if
repression is carried out by deacetylation of histones. Increasing
amounts of TSA were tested on the RARE luc reporter. In the
absence of TEL, TSA strongly increased the activity of the
promoter, suggesting that HDAC-dependent down regulation of
expression is inhibited and the promoter remains active. In the
presence of M43-TEL, however, RAR induced expression is
inhibited and TSA hardly increased the activity, suggesting that
the repression of RAR/RXR-mediated transcription by TEL
depends on other repressive mechanisms than histone deacetyla-
tion (Figure 4). Although both M1-TEL and MN1-TEL proteins
are able to bind RAR (Figure 1), no direct repression was observed
on the reporters (Figure 4, 0 mM TSA and Figure 2B). In the
presence of TSA both proteins however showed intermediate
effects: the activity of the promoter is far less stimulated by TSA.
This suggests that both M1-TEL and MN1-TEL have repressive
capacity although at a lower level compared to M43-TEL.
Discussion
RAR-RXR signaling and TEL expression are required for
proper embryonic haematological development. In adult life these
proteins are expressed throughout the body and regulate various
biological processes including cellular proliferation, differentiation,
hematopoiesis, angiogenesis and transformation [1,33,34]. RAR-
RXR regulated gene expression involves the dynamic and
continuous binding and release of co-repressors and co-activators.
Activation of RAR-RXR is the result of recruitment of co-
activators to the receptors upon binding of the ligand. The co-
activators recruit p300 a histone acetyl transferase or HAT.
Acetylation of histones then facilitates gene expression. Subse-
quent down regulation is by exchange of the co-activators for co-
repressors and these in turn recruit histone deacetylating proteins
(HDACs) [8]. In the presence of ligand only a small fraction of the
RAR-RXR target promoters is active as can be deduced from the
finding that inhibition of HDAC activity by TSA results in an at
least 8-fold increase in expression from the reporter as indicated in
Figure 4. Thus TSA apparently fixes the reporter gene in the
active state and consequently the pool of active reporter genes is
much larger than in the presence of ATRA alone. Here, we
provide evidence that TEL (ETV6) is a co-repressor for RAR. The
interplay between TEL and RAR has not been described before,
as far as we are aware. The TEL-M43 isoform actively represses
transcription of the reporter by RAR-RXR. In the presence of
TSA the activity of the reporter is only marginally increased. The
other TEL forms, TEL-M1 and the fusion protein MN1TEL also
bind RAR-RXR and they also reduce the effect of TSA. This
suggests that inhibition of RAR-RXR activity by TEL is HDAC
independent and in fact replaces HDAC activity. It is tempting to
speculate that this property of TEL is due to the recruitment of
polycomb repressor complexes through TEL’s binding partner
L(3)MBT. Alternatively it is possible that TEL prevents RAR
binding to DNA, similar to Oct-1 and Myb. Further studies should
establish which mechanism is used by TEL.
The human tumor antigen PRAME (PRreferentially expressed
Antigen in MElanoma) and HACE1 (HECT domain and Ankyrin
repeat containing E3 ubiquitin-protein ligase) were both recently
identified as a co-repressors of RAR signaling [35,36]. These co-
repressors also function via HDAC-independent mechanisms and
PRAME was shown to interact with polycomb group protein
EZH2. Despite the interesting similarity between HACE1,
PRAME and TEL as co-repressors with respect to HDAC-
independent repression, many differences are also apparent: (1)
PRAME binds RAR only in the presence of its ligand ATRA,
whereas TEL and HACE1 bind both in the presence or in the
absence of ATRA, (2) PRAME binds the LBD of RAR and
HACE1 binds the N-terminal activation function 1 (AF-1) domain
whereas TEL binds the DBD of RARa, and (3) PRAME and
HACE1 do not bind RXR, whereas TEL also binds RXRa.
We have shown that two well-studied domains of TEL, the
HLH and DBD domains, are mandatory for the interaction. Even
small point mutations in either of the domains abrogates the
binding. The binding of TEL to RARa involves the DBD of
RARa and over the last years a growing number of co-regulators
have been identified that bind this highly homologous region of
the NRs. The origin of these regulatory proteins is diverse. RIF1
and HET/SAF-B are nuclear matrix proteins and both were
shown to interact with the DBD region of the estrogen receptor
(ER). In addition, RIF1 was shown to bind the DBD of RAR and
the glucocorticoid receptor (GR) [37,38]. Binding of RIF1
translocates RAR to the nuclear matrix, thereby limiting the
amount of RAR available for DNA binding, resulting in repression
of RAR-induced transcription. Oct-1 and Myb are transcription
factors that bind to the DBDs of RXR, RAR, the vitamin D (VD)
and thyroid hormone receptor (TR) [39,40]. Both proteins prevent
the NR dimers to bind DNA, thereby reducing the fraction of
transcriptionally active NRs. In addition, Schick et al [41], have
described TEL as a repressor of Stat3 (Signal Transducer and
Activator of Transcription 3) signaling. TEL binds Stat3 and DNA
binding is not required. Stat3 repression by TEL is HDAC-
dependent, and thus different from inhibition of RAR-RXR-
mediated transcription by TEL.
In summary, we have identified TEL (ETV6) as a co-repressor
of RAR-RXR-mediated transcription. The binding of TEL to
RXRa suggests that TEL may broadly interact with NR signaling,
since RXR also dimerizes with the TR, VDR, peroxisome
Figure 4. Repression of TEL on RAR/RXR-mediated transcrip-
tion does not involve histone deacetylase activity. Increasing
amounts of TSA were tested on RARE luc reporter in the presence of
ATRA, and with and without M1-TEL, M43-TEL or MN1-TEL (120 ng).
RAR/RXR-mediated transcription was stimulated by TSA to high levels,
whereas M43-TEL prevents this. Intermediate effects were observed
with MN1-TEL and M1-TEL.
doi:10.1371/journal.pone.0023620.g004
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proliferator-activated receptor (PPAR) and a variety of other
orphan receptors [42]. If and how TEL represses other NR
signaling pathways are questions to be answered in the future. We
hypothesize that TEL bypasses deactivation of a promoter by
HDACs perhaps by recruiting polycomb complexes through one
of the L(3)MBT proteins. Thus TEL has been added to the
growing list of NR co-regulators and since both TEL and RAR
signaling are implicated in a broad spectrum of biological
processes, both in health and disease, this interaction might be
important to understand some of the biological effects of TEL and
RAR.
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